Use of replication-defective adenoviruses to develop vaccines and biotherapeutics against foot-and-mouth disease

We have developed a replication-defective human adenovirus (Ad5) vectored foot-and-mouth disease (FMD) vaccine platform that protects both swine and cattle from subsequent challenge with homologous virus after a single immunization. This Ad5-FMD vaccine has undergone testing following the requirements of the Center for Veterinary Biologics of the Animal Plant and Health Inspection Service, US Department of Agriculture, and has recently been granted a conditional license for inclusion of the vaccine in the US National Veterinary Vaccine Stockpile. In this review, we will describe the approaches we have taken to improve the potency and efficacy of this vaccine platform. Furthermore, we will discuss the development of Ad5 vector-based biotherapeutics to generate rapid protection against FMD virus prior to vaccine-induced adaptive immunity and describe the use of a combination of these approaches to stimulate both fast and long-lasting immunity.